Abstract
Introduction
The effectiveness of nivolumab plus ipilimumab with two cycles of chemotherapy (NIC) for advanced non-small cell lung cancer (NSCLC) has been demonstrated. We aimed to evaluate the cost-effectiveness of NIC for advanced NSCLC from the US payer perspective.
Methods
A Markov model has been established to predict the disease course of previously untreated advanced NSCLC. The clinical data were derived from the CheckMate 9LA trial. Cost and utility were obtained from the literature. Model outputs included the incremental cost-effectiveness ratios (ICERs), incremental monetary benefit (INMB), and incremental net-health benefit (INHB). A series of sensitivity analyses were performed to analyze the uncertainty of the model.
Results
Our results showed that NIC versus chemotherapy alone cost $264,278 and yielded an additional 0.80 quality-adjusted life-years (QALYs), which led to an ICER of $202,275/QALY gained. The INHB was − 0.28 QALY, and the INMB was − $41,865 at the threshold of $150,000/QALY. The results of one-way sensitivity analysis showed that the hazard ratio of overall survival was the most sensitive parameter.
Conclusion
NIC was unlikely to be cost-effective as a first-line treatment for patients with advanced NSCLC.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–85.
Topalian SL, Hodi FS, Brahmer JR, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. 2019;5(10):1411–20.
Bristol Myers Squibb. OPDIVO (nivolumab). Prescribing information. US Food and Drug Administration. December, 2020. 2020. https://packageinserts.bms.com/pi/pi_opdivo.pdf. Accessed 14 Apr 2021.
Leonetti A, Wever B, Mazzaschi G, et al. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Drug Resist Updat. 2019;46:100644.
Judd J, Borghaei H. Combining immunotherapy and chemotherapy for non-small cell lung cancer. Thorac Surg Clin. 2020;30(2):199–206.
Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014;21(1):15–25.
Peng J, Hamanishi J, Matsumura N, et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-kappaB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res. 2015;75(23):5034–45.
Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198–211.
Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11:139.
Arias E, Xu J. United States life tables, 2018. Natl Vital Stat Rep. 2020;69(12):1–45.
Halfhill TR. Medical-careinflationcalculator. 2021. https://www.halfhill.com/inflation_js.html. Accessed 15 Mar 2021.
Wan X, Luo X, Tan C, Zeng X, Zhang Y, Peng L. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: a United States-based cost-effectiveness analysis. Cancer. 2019;125(20):3526–34.
CMS. 2021 ASP drug pricing files. 2021. https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2021-asp-drug-pricing-files. Accessed 8 Apr 2021.
Roth JA, Sullivan SD, Lin VW, et al. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ. 2018;21(12):1238–45.
Centers for Medicare and Medicaid Services. License for use of Current Procedural Terminology, Fourth Edition (“CPT®”). https://www.cms.gov/apps/physician-fee-schedule/search/search-results.as-px?Y=4&T=0&HT=1&CT=0&H1=99213&H2=96413&M=5. Accessed 28 Jan 2021.
Wu B, Ma F. Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer. Ther Adv Med Oncol. 2020;12:1758835920916000.
Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103.
ICER. Institute for Clinical and Economic Review releases final value assessment framework for 2017–2019. 2021. https://icer.org/news-insights/press-releases/vaf-update-2017-2019/. Accessed 15 Mar 2021.
Uyl-de Groot CA, Lowenberg B. Sustainability and affordability of cancer drugs: a novel pricing model. Nat Rev Clin Oncol. 2018;15(7):405–6.
Ding D, Hu H, Liao M, et al. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of metastatic non-squamous non-small cell lung cancer. Adv Ther. 2020;37(5):2116–26.
Lin S, Luo S, Zhong L, et al. Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer. Int J Clin Pharm. 2020;42(4):1175–83.
Wan X, Luo X, Tan C, Zeng X, Zhang Y, Peng L. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: a United States-based cost-effectiveness analysis. Cancer. 2019;125(20):3526–34.
Insinga RP, Vanness DJ, Feliciano JL, Vandormael K, Traore S, Burke T. Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US. J Med Econ. 2018;21(12):1191–205.
Insinga RP, Vanness DJ, Feliciano JL, et al. Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US. Curr Med Res Opin. 2019:35(7):1241–56.
Wu B, Lu S. The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis. Transl Lung Cancer Res. 2020;9(5):1770–84.
Zeng X, Wan X, Peng L, et al. Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA. BMJ Open. 2019;9(12):e031019.
Horvath L, Pircher A. ASCO non-small lung cancer (NSCLC) personal highlights. Memo. 2020;2021:1–4.
Yang Z, Zhu Y, Xiang G, et al. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China. Expert Rev Pharmacoecon Outcomes Res. 2021:1–7. https://doi.org/10.1080/14737167.2021.1899813.
Jiang Y, Wang X. Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non-small-cell lung cancer in China. Eur J Hosp Pharm. 2020. https://doi.org/10.1136/ejhpharm-2020-002208.
Barbier MC, Pardo E, Panje CM, Gautschi O, Lupatsch JE, Swiss Group for Clinical Cancer Research. A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland. Eur J Health Econ. 2021. https://doi.org/10.1007/s10198-021-01282-4.
Goldstein DA, Chen Q, Ayer T, et al. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. J Clin Oncol. 2015;33(10):1112–8.
Ding D, Hu H, Liao M, et al. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of metastatic non-squamous non-small cell lung cancer. Adv Ther. 2020;37(5):2116–26.
Acknowledgements
Funding
The work was supported by grants from the National Natural Science Foundation of China (grant numbers 82073818 and 71874209); and the Key Science-Technology Research and Development Program of Hunan Province (grant number 2020JJ8046); and the Hunan Provincial Natural Science Foundation of China (grant number 2019JJ40411). The journal’s Rapid Service Fee was funded by the study sponsor.
Authorship
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Author’s Contributions
Study design and supervision: XW and CT; data analysis and interpretation: SL, LY, XL; data collection: LP, LW, SQ, QL; manuscript writing: YP and XZ; final approved of manuscript: All authors.
Disclosures
Ye Peng, Xiaohui Zeng, Liubao Peng, Qiao Liu, Lidan Yi, Xia Luo, Sini Li, Liting Wang, Shuxia Qin, Xiaomin Wan and Chongqing Tan declare no conflicts of interest.
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Author information
Authors and Affiliations
Corresponding authors
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Peng, Y., Zeng, X., Peng, L. et al. Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer. Adv Ther 38, 3962–3972 (2021). https://doi.org/10.1007/s12325-021-01788-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-021-01788-6